SAN FRANCISCO, Nov. 2, 2021 /PRNewswire/ -- Rune Labs, a company using aggregated brain data
to empower the development and delivery of precision medicines for
neurological and psychiatric diseases, and Medtronic
plc (NYSE:MDT), a global leader in healthcare technology,
today announced a new project designed to better understand the
effects of neurostimulation in order to improve patient care. This
collaboration will use Rune's proprietary software platform to
integrate, analyze, and display data captured from Medtronic's
Percept™ PC Neurostimulator, along with data from the StrivePD
Apple Watch application and other sources. The Medtronic Percept™
PC Neurostimulator with BrainSense™ technology* is the first and
only complete Deep Brain Stimulation (DBS) system able to
chronically capture and record brain signals while delivering
therapy to patients with neurologic disorders associated with
Parkinson's disease, essential tremor, dystonia, and epilepsy.
Rune's software platform will deliver data from Medtronic's
neurostimulation device to participating clinicians in a unique and
objective way to support patient-specific treatment decisions. This
includes the continuous monitoring of local field potentials (LFPs)
a million times smaller than DBS stimulation pulses that can
correlate with Parkinson's disease symptoms, giving doctors data
that may guide treatment. Rune's software will also integrate data
from additional sources, including a patient wearable,
patient-reported symptoms and medication dosing, and provide
participating clinicians with the ability to access a holistic view
of all of this data.
"Neuromodulation devices are adding to the large pool of
brain data available, but there has been limited progress in
utilizing this data to directly impact Parkinson's disease
treatment," said Brian Pepin,
founder and CEO, Rune Labs. "By
leveraging our software to incorporate LFP data collected from
the Medtronic PerceptTM PC neurostimulator, we
can provide participating doctors with novel clinical
information to support personalized patient care. This
collaboration represents progress in the neuromodulation space,
which currently lags behind fields such as cardiology and diabetes
in terms of both objective data utilization and remote patient
monitoring."
"We are always looking for opportunities to better serve
patients, and Rune's platform is an ideal vehicle to further our
understanding of clinically beneficial roles for BrainSense data,"
says Rob Raike, PhD, Distinguished
Scientist, Medtronic. "With the rise of virtual medicine prompted
by the COVID-19 pandemic, remote patient monitoring with objective
data has become a critical need. By adding BrainSense data to the
Rune platform as part of this project, we are taking an important
step towards improving decision support options for clinicians
caring for DBS patients. We believe this will offer unique insights
to how patients are experiencing and responding to their DBS
therapy and medical therapies in real-world environments."
Under the terms of the project, Rune
Labs will provide access to the Rune software platform to a
select number of DBS centers. The plan includes up to
1,000 patients with Parkinson's disease implanted with a
Percept PC neurostimulator. Each patient will be monitored using
the integrated software platform over a 12-month period. Patients
can use Rune's StrivePD software application on the Apple
Watch, while clinicians use the Rune clinical dashboard to monitor
and review patient data.
About Rune Labs
Rune Labs, Inc. is empowering the
development of precision medicines for Parkinson's Disease and
other neurodegenerative disorders by using its software platform to
make brain data useful at scale. We partner with academic
collaborators to optimize clinical care for patients and with
biopharma and medtech companies to enable the development of
targeted treatments for patients with brain diseases.
www.runelabs.io
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 90,000+ passionate people
across 150 countries. Our technologies and therapies treat 70
health conditions and include cardiac devices, surgical robotics,
insulin pumps, surgical tools, patient monitoring systems, and
more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative
technologies that transform the lives of two people every second,
every hour, every day. Expect more from us as we empower
insight-driven care, experiences that put people first, and better
outcomes for all. In everything we do, we are engineering the
extraordinary. For more information on Medtronic (NYSE:MDT), visit
www.Medtronic.com and follow @Medtronic on Twitter and
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
*The sensing feature of the Percept™ PC device is intended for
use in patients receiving DBS where chronically recorded
bioelectric data may provide useful, objective information
regarding patient clinical status. Signal may not be present or
measurable in all patients. Clinical benefits of brain sensing have
not been established.
Rune Labs:
runelabs@consortpartners.com
Medtronic Contacts:
Lindsey Dickinson
Public Relations
+1-612-518-4244
Ryan Weispfenning
Investor Relations
+1-763-505-4626
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rune-labs-and-medtronic-partner-to-evaluate-use-of-medtronic-brainsense-data-in-runes-software-for-precision-neurology-301413744.html
SOURCE Rune Labs